|
The PLATON pilot-study “Platform for analyzing targetable tumor mutations”: A PLATON network study. |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; MSD; Novartis; Pierre Fabre; Roche; Sanofi |
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche |
Research Funding - Novartis |
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Lilly; MSD Oncology; Roche; SERVIER |
|
Research Funding - Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss |
|
|
|
Consulting or Advisory Role - Roche; Shire |
Research Funding - Boehringer Ingelheim (Inst) |
Travel, Accommodations, Expenses - Array BioPharma; Celgene; Halozyme; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Amgen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Institut für Klinische Krebsforschung GmbH |
Consulting or Advisory Role - Bristol-Myers Squibb; Immutep; Lilly; MacroGenics; Merck Sharp & Dohme |
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group |
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Immutep; Ipsen; Lilly; Medac; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma |